Are Global Health Ltd latest results good or bad?

Global Health Ltd's latest financial results for Q4 FY26 present a complex picture of growth and challenges. The company reported a record revenue of ₹1,159.05 crores, reflecting a year-on-year growth of 24.46% and a sequential increase of 3.39%. This growth was primarily driven by higher average revenue per occupied bed and improved occupancy rates across its multi-speciality facilities. However, the operating margin, excluding other income, contracted to 21.03%, down from 24.13% in the previous year, indicating a 310 basis point decline. This margin compression is attributed to rising employee costs, which surged by 39.52% year-on-year, and a significant increase in interest expenses, which rose by 77.77% to ₹26.71 crores, marking the highest quarterly interest burden in the company's history. Net profit for the quarter stood at ₹143.99 crores, up 42% year-on-year and showing a substantial sequential profit jump of 51.54% from the previous quarter's ₹95.02 crores. While this profit increase is notable, it raises questions about the sustainability of margin expansion given the operational challenges highlighted. The company's average return on equity (ROE) of 15.69% remains strong within the hospital sector, reflecting effective capital deployment despite the capital-intensive nature of the business. However, the interest coverage ratio has deteriorated to 9.13 times, indicating a weakening ability to cover interest expenses, which is a concern for future profitability. Overall, Global Health Ltd's results illustrate a strong topline performance juxtaposed with significant margin pressures and rising costs. The company has seen an adjustment in its evaluation, reflecting the ongoing challenges in balancing growth with profitability. Investors should monitor the company's ability to sustain revenue growth while addressing the cost pressures that are impacting margins.